Novo Nordisk Cuts 9,000 Jobs Amid Wegovy Competition
Here’s a summary of the key information from the provided text:
Novo Nordisk is undergoing restructuring: The company is implementing redundancies (job cuts) as part of a shift in strategy.
New Leadership: These moves are the first major actions taken by new CEO Mike Doustdar, who recently replaced Lars Fruergaard Jørgensen. Doustdar is Iranian-born Austrian-American. Jørgensen had previously hinted at potential redundancies.
Need for Agility: Doustdar emphasizes the need for Novo Nordisk to become “faster adn more agile.”
Drug Setbacks: The company has faced disappointing results with its new obesity drug, CagriSema, which didn’t perform and also Eli Lilly’s Mounjaro in clinical trials.
Compounding Issues: Sales are also being impacted by “compounding” pharmacies in the US offering cheaper, copycat versions of weight-loss medications.
Profit Warning Expected: Analysts at Bank of America anticipate Novo Nordisk will issue another profit warning in November, doubting they’ll meet their sales forecast.